"For several years now, we've had a strategy to talk to our customers about treating people as people, not as diseases, realizing that, unfortunately, they have multiple conditions or diseases going on at one time, and that multiprogram platform approach has allowed us to actually sell more programs into a single customer." Omada Health, which went public in June, also tightened the bottom line, reducing its net loss to $3 million, or an adjusted loss of 6 cents per share, compared to a loss of $9 million in the third quarter of 2024
Results are expressed as mean standard error of the mean unless otherwise stated
As companies make more drugs, we need more reliable ways of getting it to people in a timely manner. Chase agreed that even when the national supply chain is stable, localized logistics often remain the bottleneck
Biomed Pharmacother 164:114925 He Z, Song C, Li S et al (2024) Development and application of the CRISPR-dcas13d-eIF4G translational regulatory system to inhibit ferroptosis in calcium oxalate crystal-induced kidney injury
